TY - JOUR
T1 - Cephalosporin resistance, tolerance, and approaches to improve their activities
AU - Araten, Alison H.
AU - Brooks, Rachel S.
AU - Choi, Sarah D.W.
AU - Esguerra, Laura L.
AU - Savchyn, Diana
AU - Wu, Emily J.
AU - Leon, Gabrielle
AU - Sniezek, Katherine J.
AU - Brynildsen, Mark P.
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to the Japan Antibiotics Research Association 2023.
PY - 2024/3
Y1 - 2024/3
N2 - Cephalosporins comprise a β-lactam antibiotic class whose first members were discovered in 1945 from the fungus Cephalosporium acremonium. Their clinical use for Gram-negative bacterial infections is widespread due to their ability to traverse outer membranes through porins to gain access to the periplasm and disrupt peptidoglycan synthesis. More recent members of the cephalosporin class are administered as last resort treatments for complicated urinary tract infections, MRSA, and other multi-drug resistant pathogens, such as Neisseria gonorrhoeae. Unfortunately, there has been a global increase in cephalosporin-resistant strains, heteroresistance to this drug class has been a topic of increasing concern, and tolerance and persistence are recognized as potential causes of cephalosporin treatment failure. In this review, we summarize the cephalosporin antibiotic class from discovery to their mechanisms of action, and discuss the causes of cephalosporin treatment failure, which include resistance, tolerance, and phenomena when those qualities are exhibited by only small subpopulations of bacterial cultures (heteroresistance and persistence). Further, we discuss how recent efforts with cephalosporin conjugates and combination treatments aim to reinvigorate this antibiotic class.
AB - Cephalosporins comprise a β-lactam antibiotic class whose first members were discovered in 1945 from the fungus Cephalosporium acremonium. Their clinical use for Gram-negative bacterial infections is widespread due to their ability to traverse outer membranes through porins to gain access to the periplasm and disrupt peptidoglycan synthesis. More recent members of the cephalosporin class are administered as last resort treatments for complicated urinary tract infections, MRSA, and other multi-drug resistant pathogens, such as Neisseria gonorrhoeae. Unfortunately, there has been a global increase in cephalosporin-resistant strains, heteroresistance to this drug class has been a topic of increasing concern, and tolerance and persistence are recognized as potential causes of cephalosporin treatment failure. In this review, we summarize the cephalosporin antibiotic class from discovery to their mechanisms of action, and discuss the causes of cephalosporin treatment failure, which include resistance, tolerance, and phenomena when those qualities are exhibited by only small subpopulations of bacterial cultures (heteroresistance and persistence). Further, we discuss how recent efforts with cephalosporin conjugates and combination treatments aim to reinvigorate this antibiotic class.
UR - http://www.scopus.com/inward/record.url?scp=85180200956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85180200956&partnerID=8YFLogxK
U2 - 10.1038/s41429-023-00687-y
DO - 10.1038/s41429-023-00687-y
M3 - Review article
C2 - 38114565
AN - SCOPUS:85180200956
SN - 0021-8820
VL - 77
SP - 135
EP - 146
JO - Journal of Antibiotics
JF - Journal of Antibiotics
IS - 3
ER -